PDCD1 and cancer: Cancer immunotherapy using mAbs against PD-1 (and its ligand PD-L1) has demonstrated unprecedented therapeutic benefits and helped to provide long-term durable responses in a subset of patients with multiple types of advanced cancers [9,10].